Zoetis Inc.

Equities

ZTS

US98978V1035

Pharmaceuticals

Real-time Estimate Cboe BZX 10:45:13 2024-04-16 am EDT 5-day change 1st Jan Change
152.4 USD +1.79% Intraday chart for Zoetis Inc. -8.90% -22.86%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Piper Sandler Adjusts Zoetis' Price Target to $195 From $220, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Sector Update: Health Care Stocks Lower Friday Afternoon MT
Sector Update: Health Care MT
Zoetis Shares Fall After Dog Owners Reportedly Blame Arthritis Drug Librela for Pet Illnesses MT
Zoetis Shares Slip Premarket After WSJ Report on Arthritis Drugs for Pets DJ
Zoetis Inc Files a Definitive Proxy Statement with Securities and Exchange Commission CI
Zoetis Inc: World leader in animal health Our Logo
Stifel Cuts Price Target on Zoetis to $195 From $215, Maintains Buy Rating MT
Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors CI
Zoetis Inc Receives a Shareholder Proposal from John Chevedden CI
EU Regulator Initiates Antitrust Probe on US Animal Health Company Zoetis MT
European Commission Opens Antitrust Probe Into Zoetis MT
EU Opens Antitrust Investigation Into Zoetis MT
Zoetis to Be Investigated by EU Over Possible Breach of Competition Rules -- 2nd Update DJ
EU to Investigate Zoetis Over Possible Breach of Competition Rules -- Update DJ
EU to Investigate Zoetis Over Possible Breach of Competition Rules DJ
EU targets Zoetis in antitrust investigation over dog medicines RE
Old demons return as tech takes a dive Our Logo
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys... Our Logo
Transcript : Zoetis Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:30 AM
Transcript : Zoetis Inc. Presents at Bank of America 2024 Animal Health Virtual Summit, Feb-29-2024 11:40 AM
Phew! The party continues! Our Logo
ANALYST RECOMMENDATIONS : Datadog, Doordash, Nvidia, Trimble, Walmart... Our Logo
Piper Sandler Raises Price Target on Zoetis to $220 From $215, Maintains Overweight Rating MT
Chart Zoetis Inc.
More charts
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows: - pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%); - livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%); - other (1.1%). Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%). At the end of 2022, the group has 29 production sites worldwide. The United States accounts for 53.4% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
149.8 USD
Average target price
218.3 USD
Spread / Average Target
+45.76%
Consensus
  1. Stock Market
  2. Equities
  3. ZTS Stock
  4. News Zoetis Inc.
  5. Goldman Sachs Removes Buy-Rated Zoetis From Conviction List, Adjusts Price Target to $202 From $208